Cadrenal Therapeutics
CVKD
9 hedge funds and large institutions have $752K invested in Cadrenal Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
350% more funds holding
Funds holding: 2 → 9 (+7)
8.49% more ownership
Funds ownership: 0% → 8.5% (+8.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$931K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$27.6K |
| 4 |
Virtu Financial
New York
|
+$24.1K |
| 5 |
Biltmore Family Office
Charlotte,
North Carolina
|
+$10.4K |
Top Sellers
CVKD Hedge Fund Activity: Q3 2023 in Review
9 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q3 2023, worth a combined $752K — up 175,177% from $429 a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CVKD positions and 0 closed out — a net gain of 7 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $931K.
- 9 institutional investors held Cadrenal Therapeutics (CVKD) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $752K of Cadrenal Therapeutics stock for Q3 2023, up 175,177% quarter-over-quarter.
- 7 funds opened new Cadrenal Therapeutics positions in Q3 2023 and 0 closed out, a net change of +7 holders.
- The largest Cadrenal Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $931K added.
Based on aggregated 13F filings for Q3 2023.